Aberrations in signal transduction are associated with a number of diseases, including cancer, diabetes etc. In this study we identify SLAP2 as a novel KIT interacting protein, which regulates receptor signaling by reducing the activity of its downstream signal transduction targets and by promoting degradation of the receptor. This evidence concerns the gene SLA2 and cancer.